PREVALENCE, FREQUENCY AND COST OF SELF-MONITORING OF BLOOD GLUCOSE AND ITS INFLUENCING FACTORS FOR INSULIN-TREATED DIABETES PATIENTS IN CHINA
Author(s)
Li H1, Ruan Z2, Guan X1, Guo Z3, Sun F2, Shi L1
1International Research Center of Medicinal Administration, Peking University, Beijing, China, 2Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, 3School of Pharmaceutical Sciences, Peking University, Beijing, China
OBJECTIVES:
- To describe the prevalence, frequency and cost of SMBG, and explore the factors that influence SMBG for insulin-treated diabetes patients in China.
- A questionnaire-based survey was conducted in 7 medical centres across China from June to September of 2012. Type 1 and type 2 diabetes patients treated with insulin were included in the study.
- The data were analysed by descriptive analysis, Spearman correlation analysis, K-W and M-W U test using SPSS 19.0
- Annual cost of SMBG was 1170 CNY, estimated by the market price of 5 CNY/test trip. 20.5% of patients thought the cost of test trips was the most important factor to SMBG use.
- SMBG frequency was statistically and positively correlated with frequency and doses of insulin daily use, frequency and related cost of hypoglycaemia, drug cost, frequency and cost of hospitalization and clinical visit, with P-value <0.05.
- SMBG was not conducted enough in insulin-treated diabetes patients in China.
- Economic burden of test trips was one of the main barriers to SMBG use.
- Factors influencing SMBG included insulin use, hypoglycaemia, drug costs, frequency and cost of hospitalization and clinic visit.
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PDB55
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders